An update on pediatric bronchiectasis

Danielle F. Wurzel, Anne B. Chang

    Research output: Contribution to journalReview articlepeer-review


    Introduction: The prevalence and awareness of bronchiectasis not related to cystic fibrosis (CF) is increasing and it is now recognized as a major cause of respiratory morbidity, mortality and healthcare utilization worldwide. The need to elucidate the early origins of bronchiectasis is increasingly appreciated and has been identified as an important research priority. Current treatments for pediatric bronchiectasis are limited to antimicrobials, airway clearance techniques and vaccination. Several new drugs targeting airway inflammation are currently in development. 

    Areas covered: Current management of pediatric bronchiectasis, including discussion on therapeutics, non-pharmacological interventions and preventative and surveillance strategies are covered in this review. We describe selected adult and pediatric data on bronchiectasis treatments and briefly discuss emerging therapeutics in the field. 

    Expert commentary: Despite the burden of disease, the number of studies evaluating potential treatments for bronchiectasis in children is extremely low and substantially disproportionate to that for CF. Research into the interactions between early life respiratory tract infections and the developing immune system in children is likely to reveal risk factors for bronchiectasis development and inform future preventative and therapeutic strategies. Tailoring interventions to childhood bronchiectasis is imperative to halt the disease in its origins and improve adult outcomes.

    Original languageEnglish
    Pages (from-to)517-532
    Number of pages16
    JournalExpert Review of Respiratory Medicine
    Issue number7
    Publication statusPublished - 3 Jul 2017


    Dive into the research topics of 'An update on pediatric bronchiectasis'. Together they form a unique fingerprint.

    Cite this